Stryker (NYSE:SYK) Upgraded to “Strong-Buy” at UBS Group

UBS Group upgraded shares of Stryker (NYSE:SYK) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Several other research firms have also recently weighed in on SYK. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Finally, Citigroup decreased their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $393.39.

Stryker Trading Up 2.9%

Shares of NYSE:SYK opened at $346.59 on Tuesday. Stryker has a 12 month low of $281.00 and a 12 month high of $403.92. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company’s fifty day simple moving average is $315.76 and its 200 day simple moving average is $335.22. The firm has a market cap of $132.87 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.16 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts forecast that Stryker will post 14.99 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is currently 40.74%.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently added to or reduced their stakes in SYK. VanderPol Investments L.L.C. grew its position in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC raised its holdings in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC raised its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC lifted its stake in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp grew its holdings in Stryker by 1.2% during the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.